Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer

Launched by STEFAN CARLSSON · Mar 9, 2021

Keywords

ClinConnect Summary

This clinical trial is comparing two different treatments for men whose prostate cancer has returned after surgery. One group of participants will receive standard salvage radiation therapy, while the other group will get personalized treatment based on a special imaging test called PSMA PET/CT, which helps identify cancer cells more accurately. The goal of the study is to see which treatment is more effective at lowering PSA levels (a marker for prostate cancer) and improving overall quality of life.

To be eligible for this trial, participants must be men aged 65 to 74 who have had surgery for prostate cancer and are now experiencing a slight rise in their PSA levels. They should not have had certain previous treatments, like hormone therapy or radiotherapy for their cancer. Throughout the study, participants will have regular PSA tests and complete questionnaires about their quality of life to help researchers understand the impact of the treatments. This study is currently recruiting participants.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients previously treated for prostate cancer with radical prostatectomy and now having a biochemical recurrence (BCR) defined as: PSA \>0.2 \<2.0 ng/mL, and increasing measured twice.
• • Multidisciplinary conference (MDK) decision to offer the patient SRT
• • Signed Informed Consent
• Exclusion Criteria:
• • Patients previously treated for prostate cancer with biochemical recurrence
• • Previous treatment with androgen deprivation therapy (ADT) after surgery
• • Previous pelvic radiotherapy
• • Patients with positive lymph nodes at surgery